Dianthus Therapeutics Inc
DNTH
Get informed when a big investor buys or sells
+ FollowMarket Cap$5.42B
Close$
$-2.32
102.6% downside
Current Fair Value
102.6% downsideOvervalued by 102.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $5.42 Billion |
|---|---|
| Enterprise Value | $5.31 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-4.2 |
| Beta | 0.08 |
| Outstanding Shares | 56,029,124 |
Return
| Return on Equity | -2.55% |
|---|---|
| Return on Assets | -2.47% |
| Return on Invested Capital | -17.53% |
Valuation & Multiples
| P/E Ratio | -744.69 |
|---|---|
| PEG | -1267.29 |
| Price to Sales | - |
| Price to Book Ratio | 4.54 |
| Enterprise Value to Revenue | 3683.05 |
| Enterprise Value to EBIT | -25.68 |
| Enterprise Value to Net Income | -178 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.85
Average shareholder expectationRevenue Estimate
$297,182
Average shareholder expectationNext Earnings Call
Expected Date
November 4, 2026
EPS Estimate
$-1.02
Average shareholder expectationRevenue Estimate
$400,833
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.9327▼ 17.21% |
|---|---|
| Total Calls | 251,200▲ 8.37% |
| Total Puts | 234,300▼ 8.51% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 118.01%▼ 11.48% |
|---|---|
| Total Invested | $6.43B▲ 24.22% |
| Investors Holding | 279▲ 29.00% |
ESG Score
No data
About Dianthus Therapeutics Inc
81 employees
CEO: Jason Gardner magenta therapeutics is a biotechnology company harnessing the power of stem cell science to revolutionize stem cell transplantation for patients with immune- and blood-based diseases. by creating a platform focused on key areas of trans...